Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 6, pp 1433–1442 | Cite as

A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults

  • Joseph P. Boni
  • Cathie Leister
  • Bruce Hug
  • Jaime Burns
  • Daryl Sonnichsen
Original Article



Temsirolimus, a selective inhibitor of mammalian target of rapamycin, is an approved treatment for patients with advanced renal cell carcinoma (RCC). This study assessed the effect of intravenous (i.v.) temsirolimus 25 mg, the recommended dose for patients with RCC, on the corrected QT (QTc) interval.


This 3-period crossover study enrolled healthy subjects. In periods 1 and 2, subjects received i.v. placebo either alone or with open-label oral moxifloxacin. In period 3, subjects received a single dose of temsirolimus 25 mg. The primary statistical objective was to estimate the effect of temsirolimus compared with placebo on change from time-matched baseline QTc at the end of infusion (0.5 h). Assay sensitivity was evaluated by the effect of moxifloxacin on change from time-matched baseline QTc compared with placebo.


In total, 58 subjects were enrolled. Temsirolimus had no effect on QTc interval in the primary analysis. At 11 of 12 secondary time points, the upper bound for the temsirolimus QTc 90% confidence intervals for the time-matched change from baseline difference from placebo was <10 ms, with no evidence of QTc trends or relationship to concentrations of temsirolimus or its major metabolite, sirolimus. Moxifloxacin, the positive control, produced a significant increase in the QTc interval compared with placebo 0.5–4 h post-dose (P < 0.0001). No subject had a QTc interval exceeding 450 ms or a change from baseline of >30 ms.


Therapeutic exposure to temsirolimus is not associated with clinically significant changes in QTc intervals in healthy adults.


Temsirolimus Cardiac arrhythmia Drug safety mTOR Renal cell carcinoma Targeted therapy 


  1. 1.
    Farkas AS, Nattel S (2010) Minimizing repolarization-related proarrhythmic risk in drug development and clinical practice. Drugs 70:573–603PubMedCrossRefGoogle Scholar
  2. 2.
    Salvi V, Karnad DR, Panicker GK, Kothari S (2010) Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 159:34–48PubMedCrossRefGoogle Scholar
  3. 3.
    Shah RR (2002) The significance of QT interval in drug development. Br J Clin Pharmacol 54:188–202PubMedCrossRefGoogle Scholar
  4. 4.
    Abraham RT, Gibbons JJ (2007) The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 13:3109–3114PubMedCrossRefGoogle Scholar
  5. 5.
    Boni JP, Hug B, Leister C, Sonichsen D (2009) Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations. Semin Oncol 36:S18–S25PubMedCrossRefGoogle Scholar
  6. 6.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer R, Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRefGoogle Scholar
  7. 7.
    Food and Drug Administration (2005) International Conference on Harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drug. Fed Regist 70:61134–61135Google Scholar
  8. 8.
    Hug B, Abbas R, Leister C, Burns J, Sonnichsen D (2010) A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects. Clin Cancer Res 16:4016–4023PubMedCrossRefGoogle Scholar
  9. 9.
    Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L (2007) Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications. J Clin Pharmacol 47:1430–1439PubMedCrossRefGoogle Scholar
  10. 10.
    Boni J, Abbas R, Leister C, Burns J, Jordan R, Hoffmann M, DeMaio W, Hug B (2009) Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol 64:263–270PubMedCrossRefGoogle Scholar
  11. 11.
    Torisel [package insert] (2011) Pfizer Inc, PhiladelphiaGoogle Scholar
  12. 12.
    Avelox [package insert] (2008) Bayer HealthCare Pharmaceuticals, WayneGoogle Scholar
  13. 13.
    Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14:931–937PubMedCrossRefGoogle Scholar
  14. 14.
    Evans WE, Schentag JJ, Jusko WJ (eds) (1992) Applied pharmacokinetics: principles of therapeutic drug monitoring. Lippincott Williams & Wilkins, New YorkGoogle Scholar
  15. 15.
    Zareba W, Moss AJ, Rosero SZ, Hajj-Ali R, Konecki J, Andrews M (1997) Electrocardiographic findings in patients with diphenhydramine overdose. Am J Cardiol 80:1168–1173PubMedCrossRefGoogle Scholar
  16. 16.
    Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918PubMedCrossRefGoogle Scholar
  17. 17.
    Boni JP, Leister C, Burns J, Hug B (2008) Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 98:1797–1802PubMedCrossRefGoogle Scholar
  18. 18.
    Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822–3829PubMedCrossRefGoogle Scholar
  19. 19.
    Benton RE, Sale M, Flockhart DA, Woosley RL (2000) Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther 67:413–418PubMedCrossRefGoogle Scholar
  20. 20.
    Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME (2005) Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77:76–89PubMedCrossRefGoogle Scholar
  21. 21.
    Boni JP, Zhou S, Burns J, Smith K, Liao S (2006) Integrated population pharmacokinetic analysis of temsirolimus in cancer patients following weekly IV treatments [abstract 552]. Eur J Cancer Suppl 4:167CrossRefGoogle Scholar
  22. 22.
    Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M, Schmidinger H (2008) Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 26:5204–5212PubMedCrossRefGoogle Scholar
  23. 23.
    Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332–344PubMedCrossRefGoogle Scholar
  24. 24.
    Girardi F, Franceschi E, Brandes AA (2010) Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 15:683–694PubMedCrossRefGoogle Scholar
  25. 25.
    Bello CL, Mulay M, Huang X, Patyna S, Dinolfo M, Levine S, Van VA, Toh M, Baum C, Rosen L (2009) Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic- pharmacodynamic evaluation of sunitinib. Clin Cancer Res 15:7045–7052PubMedCrossRefGoogle Scholar
  26. 26.
    Keisner SV, Shah SR (2011) Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71:443–454PubMedGoogle Scholar
  27. 27.
    Tolcher AW, Appleman LJ, Shapiro GI, Mita AC, Cihon F, Mazzu A, Sundaresan PR (2011) A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol 67:751–764PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Joseph P. Boni
    • 1
  • Cathie Leister
    • 2
  • Bruce Hug
    • 3
  • Jaime Burns
    • 4
  • Daryl Sonnichsen
    • 5
  1. 1.Clinical Pharmacology LeadPfizer IncCollegevilleUSA
  2. 2.Senior Principal Biostatistician IIPfizer IncCollegevilleUSA
  3. 3.Medical MonitorPfizer Inc (Now: CSL Behring)CollegevilleUSA
  4. 4.Clinical ScientistPfizer Inc (Now: Teva)CollegevilleUSA
  5. 5.Clinical Pharmacology Team LeadPfizer Inc (Now: Sonnichsen Pharmaceutical Associates, L.L.C.)CollegevilleUSA

Personalised recommendations